CL2013002436A1 - Proceso para preparar una forma cristalina anhidra de ((s)-1-hidroximetil-2,2-dimetilpropil)amida del acido ( 1as,5as)-2-(4-oxipirazin-2-il)-1a,2,5,5a-tetrahidro-1h-2,3-diazaciclopropa[a]pentaleno-4-carboxilico; forma cristalina; composicion farmaceutica; proceso para prepararla; solvato; y uso para tratar dolor y osteoporosis. - Google Patents
Proceso para preparar una forma cristalina anhidra de ((s)-1-hidroximetil-2,2-dimetilpropil)amida del acido ( 1as,5as)-2-(4-oxipirazin-2-il)-1a,2,5,5a-tetrahidro-1h-2,3-diazaciclopropa[a]pentaleno-4-carboxilico; forma cristalina; composicion farmaceutica; proceso para prepararla; solvato; y uso para tratar dolor y osteoporosis.Info
- Publication number
- CL2013002436A1 CL2013002436A1 CL2013002436A CL2013002436A CL2013002436A1 CL 2013002436 A1 CL2013002436 A1 CL 2013002436A1 CL 2013002436 A CL2013002436 A CL 2013002436A CL 2013002436 A CL2013002436 A CL 2013002436A CL 2013002436 A1 CL2013002436 A1 CL 2013002436A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- crystalline form
- oxipirazin
- osteoporosis
- tetrahydro
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- YZGJIENQZBJQNS-UHFFFAOYSA-N pentalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=C21 YZGJIENQZBJQNS-UHFFFAOYSA-N 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 208000004454 Hyperalgesia Diseases 0.000 abstract 3
- 208000035154 Hyperesthesia Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000009137 Behcet syndrome Diseases 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000020341 sensory perception of pain Effects 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446732P | 2011-02-25 | 2011-02-25 | |
| US201161448542P | 2011-03-02 | 2011-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002436A1 true CL2013002436A1 (es) | 2014-01-24 |
Family
ID=45841624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002436A CL2013002436A1 (es) | 2011-02-25 | 2013-08-23 | Proceso para preparar una forma cristalina anhidra de ((s)-1-hidroximetil-2,2-dimetilpropil)amida del acido ( 1as,5as)-2-(4-oxipirazin-2-il)-1a,2,5,5a-tetrahidro-1h-2,3-diazaciclopropa[a]pentaleno-4-carboxilico; forma cristalina; composicion farmaceutica; proceso para prepararla; solvato; y uso para tratar dolor y osteoporosis. |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9458136B2 (enExample) |
| EP (3) | EP4166552B1 (enExample) |
| JP (1) | JP5945554B2 (enExample) |
| KR (1) | KR102036932B1 (enExample) |
| CN (1) | CN103608343B (enExample) |
| AU (1) | AU2012222146B2 (enExample) |
| BR (1) | BR112013021549B1 (enExample) |
| CA (1) | CA2827057C (enExample) |
| CL (1) | CL2013002436A1 (enExample) |
| CO (1) | CO6852066A2 (enExample) |
| DK (1) | DK3395812T3 (enExample) |
| EA (1) | EA035989B1 (enExample) |
| ES (1) | ES2932441T3 (enExample) |
| IL (1) | IL227782A (enExample) |
| MX (1) | MX346533B (enExample) |
| MY (1) | MY165767A (enExample) |
| PH (1) | PH12013501726A1 (enExample) |
| SG (1) | SG192817A1 (enExample) |
| WO (1) | WO2012116276A1 (enExample) |
| ZA (1) | ZA201306402B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4036082A1 (en) * | 2009-08-28 | 2022-08-03 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| AU2012222146B2 (en) | 2011-02-25 | 2017-05-11 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators) |
| EP2678318A1 (en) * | 2011-02-25 | 2014-01-01 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| WO2016085941A1 (en) * | 2014-11-25 | 2016-06-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of cannabinoid receptor modulators |
| EA201892280A1 (ru) * | 2016-04-10 | 2019-04-30 | Арена Фармасьютикалз, Инк. | Способы лечения селективными агонистами cb-рецептора |
| US20200078358A1 (en) * | 2017-05-08 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds and Methods for Treatment of Visceral Pain |
| WO2018208847A1 (en) | 2017-05-08 | 2018-11-15 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of pain from inflammatory bowel disease |
| CN114391011A (zh) * | 2019-09-12 | 2022-04-22 | 四川海思科制药有限公司 | 一种六氢化苯并吡唑衍生物及其制备 |
| WO2023059610A1 (en) | 2021-10-05 | 2023-04-13 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| CZ20013833A3 (cs) | 1999-04-28 | 2002-02-13 | Aventis Pharma Deutschland Gmbh | Deriváty kyselin se dvěma arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují |
| US20040259936A1 (en) | 2001-12-07 | 2004-12-23 | Nagarkatti Leonard C | Treatment of neoplasia |
| SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| EA011307B1 (ru) | 2004-07-12 | 2009-02-27 | Кадила Хелзкэр Лимитед | Трициклические производные пиразола в качестве модуляторов каннабиноидного рецептора |
| FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| DE102004054666A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| EP1902034B1 (en) | 2005-06-02 | 2011-03-30 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| CN101238107A (zh) * | 2005-06-02 | 2008-08-06 | 格兰马克药品股份有限公司 | 新的大麻素受体配体，含有该配体的药物组合物及其制备方法 |
| WO2008003665A1 (en) | 2006-07-04 | 2008-01-10 | Janssen Pharmaceutica Nv | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
| EP2074084B1 (en) | 2006-09-25 | 2013-08-28 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
| WO2008063781A2 (en) | 2006-10-12 | 2008-05-29 | Abbott Laboratories | Chemical compounds as cannabinoid receptor ligands |
| US7928103B2 (en) | 2006-10-17 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| EP2091921A2 (en) | 2006-11-03 | 2009-08-26 | Glenmark Pharmaceuticals S.A. | Bridged bicyclic indazoles as cannabinoid receptor ligands |
| WO2008064054A2 (en) | 2006-11-21 | 2008-05-29 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| WO2008079316A1 (en) | 2006-12-20 | 2008-07-03 | Cara Therapeutics, Inc. | Tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof |
| WO2008085302A1 (en) | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| US20080214537A1 (en) | 2007-03-02 | 2008-09-04 | Cara Therapeutics, Inc. | Bridged phenanthridines |
| JP5185924B2 (ja) | 2007-03-16 | 2013-04-17 | 京セラ株式会社 | 誘電体磁器およびコンデンサ |
| US8193369B2 (en) | 2007-03-30 | 2012-06-05 | Janssen Pharmaceutica Nv | Benzimidazole cannabinoid agonists |
| WO2008157500A1 (en) | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| KR101605210B1 (ko) | 2007-06-21 | 2016-03-21 | 케러 테라퓨틱스, 인코포레이티드 | 치환된 이미다조헤테로사이클 |
| US8338623B2 (en) | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
| EP2203171A2 (en) | 2007-08-21 | 2010-07-07 | Merck Sharp & Dohme Corp. | Cb2 receptor ligands for the treatment of pain |
| UA104010C2 (en) | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
| US7741350B1 (en) | 2009-01-28 | 2010-06-22 | Cara Therapeutics, Inc. | Bicyclic pyrazolo-heterocycles |
| CN102282147B (zh) | 2009-01-28 | 2015-09-30 | 卡拉治疗学股份有限公司 | 二环吡唑并-杂环 |
| EP4036082A1 (en) | 2009-08-28 | 2022-08-03 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| WO2012116278A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| EP2678318A1 (en) | 2011-02-25 | 2014-01-01 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| AU2012222146B2 (en) | 2011-02-25 | 2017-05-11 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators) |
-
2012
- 2012-02-24 AU AU2012222146A patent/AU2012222146B2/en not_active Ceased
- 2012-02-24 DK DK18164225.7T patent/DK3395812T3/da active
- 2012-02-24 KR KR1020137025057A patent/KR102036932B1/ko not_active Expired - Fee Related
- 2012-02-24 SG SG2013062427A patent/SG192817A1/en unknown
- 2012-02-24 CN CN201280020512.3A patent/CN103608343B/zh not_active Expired - Fee Related
- 2012-02-24 US US14/001,133 patent/US9458136B2/en active Active
- 2012-02-24 ES ES18164225T patent/ES2932441T3/es active Active
- 2012-02-24 MX MX2013009760A patent/MX346533B/es active IP Right Grant
- 2012-02-24 WO PCT/US2012/026506 patent/WO2012116276A1/en not_active Ceased
- 2012-02-24 CA CA2827057A patent/CA2827057C/en active Active
- 2012-02-24 EP EP22197435.5A patent/EP4166552B1/en active Active
- 2012-02-24 EA EA201391233A patent/EA035989B1/ru not_active IP Right Cessation
- 2012-02-24 EP EP12709201.3A patent/EP2678330A1/en not_active Withdrawn
- 2012-02-24 EP EP18164225.7A patent/EP3395812B8/en active Active
- 2012-02-24 JP JP2013555597A patent/JP5945554B2/ja active Active
- 2012-02-24 BR BR112013021549-6A patent/BR112013021549B1/pt not_active IP Right Cessation
- 2012-02-24 PH PH1/2013/501726A patent/PH12013501726A1/en unknown
- 2012-02-24 MY MYPI2013003122A patent/MY165767A/en unknown
-
2013
- 2013-08-04 IL IL227782A patent/IL227782A/en active IP Right Grant
- 2013-08-23 CL CL2013002436A patent/CL2013002436A1/es unknown
- 2013-08-23 ZA ZA2013/06402A patent/ZA201306402B/en unknown
- 2013-09-10 CO CO13214674A patent/CO6852066A2/es active IP Right Grant
-
2016
- 2016-08-26 US US15/248,300 patent/US10183930B2/en active Active
-
2018
- 2018-12-10 US US16/214,388 patent/US10981895B2/en active Active
-
2021
- 2021-03-16 US US17/202,946 patent/US11560369B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002436A1 (es) | Proceso para preparar una forma cristalina anhidra de ((s)-1-hidroximetil-2,2-dimetilpropil)amida del acido ( 1as,5as)-2-(4-oxipirazin-2-il)-1a,2,5,5a-tetrahidro-1h-2,3-diazaciclopropa[a]pentaleno-4-carboxilico; forma cristalina; composicion farmaceutica; proceso para prepararla; solvato; y uso para tratar dolor y osteoporosis. | |
| CL2016003247A1 (es) | Composiciones y métodos para la expresión de arns guía usando el promotor h1 | |
| MX395148B (es) | Método para sintetizar los análogos de hormona tiroidea y leucocitos polimorfonucleares de los mismos. | |
| MX369747B (es) | Modificación dirigida del genoma de rata. | |
| MY159252A (en) | Process for the preparation of dopo-derived compounds and compositions thereof | |
| MX2009010361A (es) | Anticuerpos il-12 anti-humanos cristalinos. | |
| MX2013013144A (es) | Metodo para la produccion de un dimero mdi. | |
| MX377644B (es) | 6.7.beta-epóxidos esteroideos como intermedios químicos. | |
| AR090056A1 (es) | Anticuerpos anti-cxcr3 | |
| BR112015003393A2 (pt) | pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n | |
| IN2015DN01700A (enExample) | ||
| PH12013500694A1 (en) | Process for manufacturing dihydropteridinones and intermediates thereof | |
| MY169924A (en) | Clear hydrophobic tpu | |
| IN2014DN02166A (enExample) | ||
| IN2014MN02314A (enExample) | ||
| JP6519594B2 (ja) | イソシアネート化合物の製造方法 | |
| MX2023009372A (es) | Proceso para la preparacion de compuestos enlazantes de farmaco. | |
| BR112015010455A2 (pt) | método para produção, isolamento e purificação de anti-triptase humana recombinante (osraat) a partir de sementes de arroz | |
| PH12013500001A1 (en) | Formulations | |
| IN2014DN08226A (enExample) | ||
| PH12016500749A1 (en) | A method for preparing an intermediate of iopromide | |
| PH12021550022A1 (en) | Spirobiindane derivatives and a process for preparation thereof | |
| Kovaliskaia et al. | (-)-Sclareol conversion in the Ritter’s reaction conditions | |
| WO2015075693A8 (en) | Process for the synthesis of (11 beta,17alpha)-17-acetoxy-11 -methyl-19-norpregn-4-en-3,20-dione | |
| JP2014209191A5 (ja) | 静電荷像現像用トナーの製造方法 |